These efforts include the analysis of patients’ immune profiles at the single-cell level and the utilization of artificial intelligence to assess biomarkers such as the patient’s tumor mutational burden, PD-L1 tumor proportion score, history of systemic therapy, blood albumin level, neutrophil-to-lymphocyte ratio, age, sex, and cancer type [89,90]. Here, ALB is linked to neoplasm.